Floatz logo

Daunomycin

Acute Myeloblastic Leukemia Without Maturation

National Cancer Institute (NCI)Small moleculePhase 3Active
BBB
77/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
68/ 100
Competitive Position
95/ 100

Competitive context

4 Active assets in the Acute Myeloblastic Leukemia Without Maturation cohort.

Asset / SponsorPhaseRating
Etoposide
Stanford University
Phase 3BBB
Cytarabine
Northwestern University
Phase 3BBB
Cyclophosphamide
Fred Hutchinson Cancer Center
Phase 3BBB
Idarubicin
Bruno C. Medeiros
Phase 3BBB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 3BBB

View all 50 →

Same molecule, other indications

Daunomycin is also rated in:

acute myeloid leukemia by FAB classificationActive
BBB
Indicative · Phase 3
78 / 100
View asset →
acute myeloid leukemia with 11q23 abnormalitiesActive
BBB
Indicative · Phase 3
77 / 100
View asset →
acute monocytic leukemiaActive
BBB
Indicative · Phase 3
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →